l e t t e r s
Almost all infectious diseases are initiated at mucosal surfaces, yet intramuscular or subcutaneous vaccination usually provides only minimal protection at sites of infection owing to suboptimal activation of the mucosal immune system. The neonatal Fc receptor (FcRn) mediates the transport of IgG across polarized epithelial cells lining mucosal surfaces. We mimicked this process by fusing a model antigen, herpes simplex virus type-2 (HSV-2) glycoprotein gD, to an IgG Fc fragment. Intranasal immunization, together with the adjuvant CpG, completely protected wild-type, but not FcRn knockout, mice after intravaginal challenge with virulent HSV-2 186. This immunization strategy induced efficient mucosal and systemic antibody, B-and T-cell immune responses, with stable protection for at least 6 months after vaccination in most of the immunized animals. The FcRn-IgG transcellular transport pathway may provide a general delivery route for subunit vaccines against many mucosal pathogens.
Vaccines that protect against infectious agents entering the body at mucosal surfaces must induce both mucosal and systemic immune responses to cope with early infection and pathogen spread [1] [2] [3] [4] . The close association between mucosal epithelial cells and the immune effector cells within the laminar propria [1] [2] [3] suggests that delivery of immunogens through the mucosal surface would be an ideal approach to achieve mucosal and, potentially, systemic immunity. However, the intercellular tight junctions of epithelial monolayers lining the mucosal surfaces render them impervious to macromolecule diffusion 5 . One approach to circumvent this problem involves targeting mucosal vaccines onto differentiated microfold (sometimes called 'M') cells that punctuate the mucosal epithelium 6 . However, because columnar epithelial cells make up the great majority of mucosal surfaces, alternative mucosal vaccine delivery strategies that target these abundant epithelial cells may increase the efficacy of mucosal vaccines.
FcRn allows fetuses or newborns to obtain maternal IgG through the placental or intestinal route 7, 8 . However, the receptor can also transport IgG antibody across mucosal surfaces in adult life [9] [10] [11] [12] and confer resistance to intestinal pathogens 12 . The observation that FcRn can transport IgG across mucosal epithelia suggested to us that fusion of an antigen to IgG Fc may enable FcRn-mediated transport of the antigen across the mucosal barrier. To test this possibility, we worked with the model pathogen HSV-2, which initiates infection primarily at the mucosa of the genital tract 4 . The model antigen, HSV-2 gD, is important in early viral infection and a target for both humoral and cellular immunity. We determined the ability of FcRn to deliver a fusion of gD to the Fc fragment across the respiratory mucosal barrier and then further defined the protective immune responses and mechanisms relevant to this mode of mucosal vaccine delivery.
To target gD for FcRn-mediated uptake, we first generated the fusion protein, gD-Fc/wt, by cloning the extracellular domain of HSV-2 gD in frame with a modified form of the mouse IgG2a Fc fragment ( Supplementary Fig. 1 ). We also generated a similarly modified gD-Fc/mut fusion protein, which cannot bind FcRn owing to H→A substitutions at positions 310 and 433 (ref. 13) . In both cases, the complement C1q-binding motif was eliminated to abrogate C1q binding 14 (Supplementary Fig. 1a ). To ascertain whether the gD-Fc/wt, but not the gD-Fc/mut, fusion proteins were transported by FcRn, we assayed for FcRn-dependent transcytosis of intact gD-Fc/wt in inner medullary collecting duct cells expressing FcRn 15 ( Supplementary  Fig. 2a) . We then determined whether the gD-Fc/wt reached the bloodstream after intranasal inoculation. We confirmed FcRn expression in mouse trachea and lung and its absence in the adult intestine (Supplementary Fig. 2b ). After intranasal (i.n.) administration of 20 µg of either gD, gD-Fc/mut or gD-Fc/wt protein in FcRn WT and FcRn knockout mice 16 , we noted substantial gD-Fc/wt accumulation in the sera of FcRn WT mice only (Supplementary Fig. 2c ). These results showed that efficient delivery of gD across the respiratory barrier to the bloodstream was dependent on the Fc moiety and its ability to interact with FcRn.
Engagement of FcRn greatly increased the efficiency by which gD antigens induced antigen-specific antibody and cellular immune responses. We then determined whether FcRn-dependent transport augmented the potential of the gD protein to mount an immune response. Mice were immunized i.n. with gD-Fc, gD protein or PBS, all in combination with CpG, and received boosters after 2 weeks. The free gD protein, not linked to an Fc fragment, allowed us to both evaluate FcRn-independent effects in vivo and determine the magnitude of any observed enhancement in immune responses conferred by fusion to Fc and recognition by FcRn. Because at least some immature dendritic cells are immunologically tolerant in vivo, we co-administered CpG, a ligand for Toll-like receptor 9, in an effort to overcome possible mucosal tolerance 17 . In a different study, we found that co-administration of CpG oligonucleotides with an Fc fusion efficient mucosal vaccination mediated by the neonatal Fc receptor l e t t e r s protein was required to induce a robust IgG response (unpublished data). Significantly (P < 0.01) higher titers of IgG were seen in the gD-Fc/wt-immunized mice when compared with the gD-, gD-Fc/mut-, gD-Fc/wt/KO-immunized and PBS-treated groups (Fig. 1a) . Moreover, sera from the gD-Fc/wt-immunized mice exhibited strong neutralizing activity (Fig. 1b) and after passive transfer, protected animals from intravaginal challenge more efficiently than sera from all other groups (Supplementary Fig. 3 ). Likewise, mice immunized with gD-Fc/wt had a significantly higher frequency (P < 0.01) of IFN-γ-producing CD4 + and CD8 + splenic T cells in response to gD stimulation, relative to the other groups (Fig. 1c) . The cytokine responses were dominated by IFN-γ and interleukin (IL)-2; there was little IL-4 production (Fig. 1d) . The existence of this dominant T-helper-1 cell cytokine response was also supported by a major IgG2a subclass in the sera of the immunized mice ( Supplementary  Fig. 4 ). It remains uncertain whether this polarized T-cell response was caused by mucosal immunization by means of FcRn targeting or, more likely, by the CpG used as adjuvant 17 .
That FcRn-targeted mucosal delivery of subunit vaccine elicited a strong mucosal immune response is supported by four lines of evidence.
First, to ascertain the ability of the FcRn-targeted mucosal immunization to induce local humoral immune responses, we monitored the activated germinal center reaction in the mediastinal lymph nodes (MeLNs) and spleens 10 d after the boost, as the nasopharynxassociated lymphoid tissue and MeLNs that drain the lungs are where mucosal immune responses are initiated against i.n. administered antigens 18 . Activated germinal centers are characterized by the presence of peanut agglutinin (PNA)-positive areas and highlevel expression of FAS apoptotic death receptor in activated B cells (B220 + ) 19 . The gD-Fc/wt immunization induced a substantially higher percentage of FAS + PNA + B220 + B cells in the MeLN or spleen in comparison with that of other groups (Fig. 2a) , which was further validated by immunofluorescence imaging (Fig. 2b) . In addition, the germinal center structure in the MeLNs in WT mice immunized by gD-Fc/wt was sustained much longer in comparison with that of other groups (Fig. 2c) . Administration of CpG alone failed to elicit appreciable formation of germinal centers in the draining MeLNs, spleens or lungs (Supplementary Fig. 5 ). Because the formation and maintenance of germinal centers generally lead to the differentiation of memory B cells and long-lived plasma cells, we also examined the mesenteric, cervical and inguinal lymph nodes. We did not detect germinal center formation or a significant number of IFN-γ-secreting T cells at those sites.
Second, it has been shown that i.n. administered antigens can induce bronchus-associated lymphoid tissue (iBALT) in the lung, which is similar to germinal center structures 19 . Such germinal center-like structures could be detected in the lungs of gD-Fc/wt-, but not gD-Fc/mut-immunized mice or other groups of immunized animals ( Fig. 2d and Supplementary Fig. 5 ). The germinal centerlike iBALT in the lung was most likely induced locally because of the presence of the transported gD antigen in the MeLNs and lung.
Third, to assess the ability of FcRn-targeted mucosal immunization to induce gD-specific antibody in mucosal secretions, we collected bronchial alveolar lavage (BAL) and vaginal washings 10 d after the boost and analyzed both for gD-specific IgG and IgA by enzymelinked immunosorbent assay (ELISA). Significantly (P < 0.01) increased levels of gD-specific IgG were present in the BAL and vaginal washings (Supplementary Fig. 6 ) of the gD-Fc/wt-immunized mice. WT, but not FcRn knockout, mice that received gD-Fc/wt had high levels of gD-specific IgG in BAL and vaginal washings (P < 0.01; Supplementary Fig. 6 ), suggesting that the induction of mucosal IgG is mediated by FcRn. IgG levels in BAL and vaginal washings were much higher than levels of IgA (Supplementary Fig. 6 ).
Fourth, with respect to T-cell immune responses in the lung and MeLNs, 4 d after the boost we detected significantly (P < 0.01) more IFN-γ-producing CD4 + and CD8 + T cells (Fig. 2e,f 
FcRn produced strong antibody as well as T-cell mucosal immune responses. An efficient protective vaccine must induce immunity in the mucosa to block viral entry. FcRn-targeted mucosal immunization may provide an efficient approach for the development of such protective mucosal vaccines. In addition to humoral and cell-mediated immunity at the mucosal delivery site, an effective mucosal subunit vaccine should also elicit immunity in systemic compartments that can access mucosal tissues distant from the immunization site [1] [2] [3] . Studies have found that mucosal immunization using the intranasal route is effective for generating antibody and T-cell immune responses in the female l e t t e r s genital tract 1,2,4 . Perhaps intranasal immunization stimulates cells in the nasopharynx-associated lymphoid tissue and MeLNs, leading to the migration of antibody-secreting cells and T cells generated in the airway into the genital tract 20 . We intravaginally challenged immunized mice with a lethal dose of HSV-2 186 strain 4 weeks after the boost. All FcRn WT mice (n = 15) immunized with gD-Fc/wt survived with no obvious symptoms (Supplementary Fig. 7a ), whereas gDFc/wt-immunized FcRn knockout mice (n = 15) were incompletely protected (Fig. 3a) . These data indicate that full protection is dependent on FcRn. Additionally, virus titers measured in the vaginal washings showed that the gD-Fc/wt-immunized mice had eliminated the virus by day 4 after challenge ( Fig. 3b) , whereas substantial viral levels remained in the other groups of mice through day 6. Several immune mechanisms may account for the protection of the distal vaginal mucosa. First, both mucosal and systemic antibody responses may play an important protective role. The sera passively transferred from the gD-Fc-immunized mice conferred a high level of protection (Supplementary Fig. 3 ) and a considerable amount of gD-specific IgG appeared in the vaginal secretions ( Supplementary  Fig. 6 ). After immunization with attenuated HSV-2, IgG contributes the majority of protection in mouse vaginal secretions 20 . Second, the presence of T lymphocytes in the vaginal epithelium of HSV-2-challenged mice coincided with virus clearance. IFN-γ is clearly indispensable for resistance to HSV-2 infections 21 . The gD-Fc/wt protein induced a significantly higher frequency of IFN-γ-producing CD4 + and CD8 + T cells in the vaginal tissues from the challenged mice (Fig. 3c) . Overall these results demonstrate that FcRn-targeted mucosal immunization efficiently induced protective immunity.
Our studies further suggested that FcRn-targeted mucosal delivery of vaccine engendered an effective memory immune response. Immunological memory 22, 23 has been a concern in protein-based subunit mucosal vaccine development because although preparations frequently elicit immunity immediately after vaccination, protection decreases rapidly. A striking feature of our study is that FcRn-targeted mucosal immunization promoted and sustained high levels of gDspecific plasma cells and memory B and T cells. First, gD-Fc/wtimmunized mice developed considerably higher numbers of splenic memory B cells responsive to gD stimulation 6 months after the boost (Fig. 4a) . Using enzyme-linked immunosorbent spot (ELISPOT), we also found the significantly (P < 0.01) higher number of gD-specific, IgG-secreting plasma cells in the bone marrow of mice immunized with gD-Fc/wt ( Fig. 4b and Supplementary Fig. 8 ). It remains to be determined if gD-specific, IgA-secreting plasma cells also develop. 
Second, higher titers of gD-specific IgG were maintained for 6 months after the boost in the mice immunized with the gD-Fc/wt (Fig. 4c) . Both the increase in germinal center and memory B cells in the spleen and the existence of long-lived plasma cells in the bone marrow niche can account for the maintenance of high levels of gD-specific IgG in circulation. Third, we detected large numbers of CD4 + (Fig. 4d) and CD8 + (Fig. 4d) memory T-cell proliferation by carboxyfluorescein diacetate succinimidyl ester (CFSE) in response to gD recall in the mice immunized with gD-Fc/wt, but not in any of the other groups. This result was also verified by considerably increased numbers of actively proliferating T cells over time (Supplementary Fig. 9 ). These data indicate that the gD-specific T cells had maintained proliferative potential at least 6 months after the boost. Although the reason for the high memory T-cell activity is not completely clear, IL-2-producing T cells formed in the responding T-cell population ( Supplementary  Fig. 10 ) may be important because IL-2 is important in the successful long-term survival of memory T cells in vivo 24 . Fourth, to test if the memory immune response provided protection, we again intravaginally challenged the immunized mice with HSV-2 186 strain 6 months after the boost. Mice immunized with the gD-Fc/wt proteins exhibited less severe disease symptoms (Supplementary Fig. 7b ) and had 80% survival (Fig. 4e) , whereas the majority of mice in other groups succumbed to lethal mucosal infection.
Overall, our study shows that the FcRn/IgG transport pathway can be exploited to greatly enhance the efficacy of mucosally administered vaccines. Previous studies have taken advantage of Fc fusion proteins to augment the T-cell immune response to myelin basic protein 25 , and mucosally administered inactivated Francisella tularensis live vaccine strain/antibody immune complexes have been shown to enhance protection against a highly virulent strain 26 . We have shown that FcRn-targeted mucosal immunization differs considerably between WT and FcRn knockout mice or the gD-Fc/wt-and the gDFc/mut-immunized mice in terms of mucosal and systemic immune responses, cytokine expression profiles, the maintenance of T-and B-cell memory and long-lived bone marrow plasma cells, and resistance to infection. We establish this principle using a modified form of the mouse IgG2a Fc fragment to facilitate the vaccine antigen delivery across the mucosal barrier. Earlier studies have shown intranasal and intravaginal immunization with gD or gB proteins in combination with CpG elicited immune responses and conferred partial protection to subsequent vaginal challenge with HSV-2 (refs. [27] [28] [29] [30] . The mechanism by which 'plain' gD or gB proteins crossed the airway or female genital epithelial barrier in those studies is not clear. The treatment of mice with agents, such as volatile anesthetics halothane and isoflurane or 0.5% Tween [27] [28] [29] [30] , could compromise the integrity of the alveolo-capillary or mucosal epithelial barrier 31, 32 . Moreover, injections with Depo-Provera before vaginal immunization [28] [29] [30] may affect the integrity of cell junctions between the vaginal epithelial cells 4 . In agreement with a previous report 33 , our other studies on examinations of the effect of CpG on protein transport across the nasal/tracheal mucosa (unpublished data) are not consistent with an affect of CpG on mucosal permeability or passive transfer. Our results document the benefits of FcRn targeting to maximize the potential of mucosally administered vaccines to counteract mucosal pathogens.
We suggest the following model for FcRn-targeted immunization (Fig. 4f) . In general, mucosal dendritic cells capture antigens in mucosal-associated lymphoid tissues, and migrate to draining lymph nodes where they can activate T cells 34, 35 and initiate the cognate B-cell response. Persistence of vaccine antigens can facilitate longterm memory immune responses 22, 23 . Thus, although FcRn-mediated transport is necessary for effective mucosal immunization, the ability of FcRn to protect gD-Fc/wt proteins from degradation may further support the development of systemic immunity by increasing the persistence of gD-Fc/wt in circulation. Furthermore, this same protection property may augment long-term humoral immunity by maintaining high levels of systemic IgG antibodies specific for gD-Fc/wt. It remains to be determined whether this delivery method can augment preexisting immunity. Our findings suggest that FcRn-targeted mucosal immunization may be an effective strategy for maximizing the efficacy of vaccinations directed against a broad range of mucosal pathogens.
MeTHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
oNLINe MeTHoDS Cells, antibodies and virus. Inner medullary collecting duct (IMCD) cell line and IMCD cells expressing rat FcRn were obtained from Neil Simister. Vero and Chinese hamster ovary (CHO-K) cells were purchased from American Tissue Culture Collection (ATCC). IMCD, Vero and CHO cells were maintained in DMEM complete medium (Invitrogen Life Technologies) supplemented with 10 mM HEPES, 10% FBS, 2 mM l-glutamine, nonessential amino acids, and penicillin (0.1 µg/ml)/streptomycin (0.292 µg/ml). Recombinant IMCD and CHO cells were grown in 400 µg/ml of G418, when necessary. Cells from spleen or bone marrow were grown in complete RPMI 1640 medium. HSV-2 strain 186 was from Lawrence Stanberry and HSV-2 stocks were prepared by infection of Vero cell monolayers at a multiplicity of infection (MOI) of 0.01. All cells and viruses were grown in a humidified atmosphere of 5% CO 2 at 37 °C. Affinity-purified antibody for mouse FcRn was made as previously described 30 . Horseradish peroxidase (HRP)-conjugated donkey antirabbit or rabbit anti-mouse antibody was purchased from Pierce (Rockland). Purified mouse IgG and chicken IgY was from Rockland Laboratories, and HRP-conjugated goat anti-mouse IgG1, IgG2a and IgG3 were from Southern Biotech. All DNA-modifying enzymes were purchased from New England Biolabs. Purified HSV-2 glycoprotein D was purchased from Meridian Life Science.
Expression of gD-Fc fusion proteins.
The cDNA encoding the extracellular domain of HSV-2 gD (26-340 aa) was amplified by PCR from a plasmid provided by Patricia G. Spear using the primer pair (5′-CCCAAGCTTACCA TGGGGCGTTTGACCTCCGGCGTC-3′, 5′-AGATCCCGAGCCACCTCCT CCGGACCCACCCCCGCCTGATCCGCCCGGGTTGCTGGGGG-3′). The antisense primer introduces an extension with 14 codons for glycine and serine residues (GSGGGGSGGGGSGS). The Fc-fragment of mouse IgG2a containing the hinge, an extended CH2 and a CH3 domain was amplified by RT-PCR from the OKT3 hybridoma. The mouse IgG2a Fc fragment was used because mouse IgG2a, but not IgG1, is capable of binding mouse FcγRI, a high-affinity receptor for IgG. Similarly, the forward primer for IgG2a Fc has complementary glycine and serine codons for gD. A mutant Fc (HQ310 and HN433), unable to bind mouse FcRn, was made by oligonucleotide site-directed mutagenesis (Clontech) and designated as an Fc/mut. To construct a nonlytic Fc fragment, oligonucleotide site-directed mutagenesis was used to replace the C1q binding motif Glu318, Lys320, Lys322 with Ala residues 14 . Fusions were then performed in a PCR-based gene assembly approach by mixing the cDNA for gD and the Fc fragment. All these DNA fragments were ligated into the pCDNA3 vector. Each construct was verified by DNA sequencing.
The plasmids containing the chimeric gD-Fc fragment were transfected into CHO cells. G418-resistant clones were selected for secretion of gD-Fc fusion protein. SDS-PAGE and western blot analysis were performed to assess the recombinant fusion proteins in serum-free medium (Invitrogen). The highest secreting clones were screened. Recombinant proteins were purified from CHO cell supernatants by affinity chromatography using Protein A Sepharose 4 Fast Flow (Amersham) or goat anti-mouse IgG affinity column (Rockland). Protein concentration was measured with Coomassie (Bradford) protein assay kit (Pierce) using mouse IgG2a as standard.
Western blot analysis and SDS-PAGE gel electrophoresis. The proteins or cell lysates were resolved on a 12% SDS-PAGE gel under reducing or nonreducing conditions. Proteins were transferred onto a nitrocellulose membrane (Schleicher & Schuell). The membranes were blocked with 5% nonfat milk, probed separately with anti-gD, anti-IgG Fc antibody or anti-mouse FcRn for 1 h, and followed by incubation with HRP-conjugated rabbit anti-mouse or donkey anti-rabbit antibodies. All blocking, incubation and washing were performed in PBST solution (PBS and 0.05% Tween 20). Proteins were visualized by enhanced chemiluminescence (ECL) (Pierce).
In vitro and in vivo transcytosis. The in vitro IgG transport assay was performed as a modification of previously described methods 15, 36 . IMCD cells expressing rat FcRn were grown on transwell filter inserts (Corning Costar) to form a monolayer exhibiting transepithelial electrical resistances (TER, 300 Ω.cm 2 ). TER was measured using a tissue-resistance measurement equipped with planar electrodes (World Precision Instruments). Monolayers were equilibrated in Hanks' balanced salt solution. Fusion proteins (50 µg/ml) were applied to the apical compartment, and incubated with DMEM medium supplied with or without 1 mg/ml of mouse IgG or chicken IgY as competitors for 2 h at 37 °C degree. Transported proteins were sampled from the basolateral chamber and analyzed by reducing SDS-PAGE and western blot-ECL. For in vivo transport, the biotinylated 20 µg of fusion proteins or gD alone in 20 µl of PBS were administered i.n. into the mice that were anesthetized with 100 µl of avertin (40 mg/ml). At indicated time points or 8 h later, transported proteins in sera were determined by ELISA.
Mouse immunization and virus challenge. Six-to eight-week-old female inbred C57BL/6 mice were purchased from Charles River. FcRn knockout mice on a C57BL/6 background 16 were from the Jackson Laboratory. All mice were housed in the animal resources facility at the University of Maryland. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee. All proteins and PBS were mixed with immunostimulatory DNA rich in CG motifs CpG oligonucleotide 1826 (abbreviated CpG) to overcome possible mucosal immune tolerance 37 . Groups of five mice were immunized i.n. with 20 µl of 20 µg gD-Fc/wt, gD-Fc/mut, or recombinant gD alone or in combination with 20 µg CpG (5′-TCCATGACGTTCCTGACG TT-3′) (Invitrogen) per immunization at weeks 0 and 2 with an intraperitoneal injection of 100 µl of avertin (40 mg/ml). An additional group of five mice was mock-immunized with PBS following the same schedule. Mice were kept on their backs under anesthesia to allow the inoculum to be taken up.
Mice were inoculated with viruses intravaginally as described previously 27, 38 . Briefly, each mouse was subcutaneously treated with 3 mg of medroxyprogesterone acetate (Depo-Provera) 10 d before virus inoculation. Hormonal pretreatment was necessary to induce susceptibility of mice to genital HSV-2 inoculation, which may cause thinning of the genital epithelium or induction of the HSV entry receptor, nectin-1, on vaginal epithelial cells. Mice anesthetized by avertin (40 mg/ml, Sigma) were infected intravaginally with 1 × 10 4 plaque-forming unit (p.f.u.)/100 µl of HSV-2 strain 186. Mice were kept on their backs under the influence of anesthesia for 45 min to allow infection. Mice were monitored for 15 d for disease and death. Mice exhibiting severe disease symptom were euthanized. For virus titration, virus was inoculated into Vero cells and incubated for 45 min at 37 °C. The cells were washed and DMEM containing 0.8% methylcellulose and 2% FBS was added to overlay the cells. The cells were cultured for 3 d, the overlay was removed, and the cells were fixed with 3.7% formaldehyde for 1 h, and stained with 1% crystal violet.
Preparation of single-cell suspensions from lymph nodes, spleen, lung and vaginal tissues. Spleens and lymph nodes 39 were made into single-cell suspensions by passage through a sterile mesh screen. Cells were resuspended in Hanks' balanced salt solution (HBSS) and counted by trypan blue dye exclusion. For each experiment, cells were generally pooled from 3-5 mice in each group. For preparation of single-cell suspensions from the lung, mice were anesthetized with 400 µl of avertin (40 mg/ml) by intraperitoneal injection. Lungs were perfused with 10 ml PBS through the right ventricle, removed, minced with blades, and incubated with HBSS containing 2.5 mM HEPES and 1.3 mM EDTA at 37 °C for 30 min, followed by treatment at 37 °C for 1 h with 2.5 mg/ml collagenase D (Roche) in RPMI 1640 medium containing 5% FBS. The resulting cells were filtered through a 70-µm cell strainer (BD Biosciences) and used for fluorescence-activated cell sorting (FACS) analysis.
For isolation of vaginal cells, the vagina was excised, cut longitudinally and minced with a sterile scalpel in complete RPMI 1640 culture medium. Minced tissues (epithelium and lamina propria) were digested in complete medium with sterile 0.25% collagenase D (Sigma). Digestion was accomplished with shaking incubation at 37 °C for 30 min. After digestion, tissues and cells were filtered through a sterile gauze mesh and washed with RPMI 1640 medium, and additional tissue debris was excluded by slow-speed centrifugation for 1 min. Cells were collected from the supernatant by centrifugation, resuspended in HBSS and counted by trypan blue dye exclusion.
Flow cytometry. Single-cell suspensions from the spleen, lung or vaginal tissues were collected and cells were spun down. Erythrocytes were then lysed in 0.14 M NH 4 Cl, 0.017 M Tris-HCl at pH 7.2 on ice for 5 min.
